UGT1A1基因多态性与伊立替康临床用药安全性及疗效的关系.pdf

UGT1A1基因多态性与伊立替康临床用药安全性及疗效的关系.pdf

UGT1A1基因多态性与伊立替康临床用药安全性及疗效的关系.pdf

· 252 · 杨孟丹 ,等 UGTIA1基因多态性与伊立替康临床用药安全性及疗效的关系 l,1. [9] ChongCC,WongGL,LaiPB.Impactofantiviral therapyonpost— [2] ThatishettyAV,AgrestiN,OBrien CB.Chemotherapy—induced hepatectomyoutcomeofrhepatitisB ——relatedhepatocellularcarci— hepatotoxieity[J].ClinLiverDis,2013,17(4):671—686. noma[J].worldJGastroenterol,2014,20(20):6O06—6012. [3] CooperativeGroup ofLiverand GallbladderDiseaseofDigestive [10] CommitteeofExpelsontheDrugResistanceofHepatitisB Vi-

文档评论(0)

1亿VIP精品文档

相关文档